These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 7746194)

  • 21. Sources of bias in the economic analysis of new drugs. Health Outcomes Committee Pharmaceutical Research and Manufacturers of America, Washington, DC.
    Gagnon JP
    JAMA; 2000 Mar; 283(11):1423; author reply 1424. PubMed ID: 10732925
    [No Abstract]   [Full Text] [Related]  

  • 22. Market watch: Upcoming market catalysts in Q3 2016.
    Ranj T
    Nat Rev Drug Discov; 2016 Jul; 15(7):449. PubMed ID: 27282354
    [No Abstract]   [Full Text] [Related]  

  • 23. Funding arrangements for pharmaceuticals: can economic evaluation promote efficiency?
    Viney R
    Aust Health Rev; 2001; 24(2):21-4. PubMed ID: 11496466
    [No Abstract]   [Full Text] [Related]  

  • 24. [Does the public sector have an independent research role in the development of drugs?].
    Poulsen HE; Grønlykke TB
    Ugeskr Laeger; 2003 Apr; 165(16):1674-6. PubMed ID: 12756828
    [TBL] [Abstract][Full Text] [Related]  

  • 25. And on the cover of the guide were two words in red--don't panic.
    Harvey R
    Aust Health Rev; 2001; 24(2):15-20. PubMed ID: 11496457
    [No Abstract]   [Full Text] [Related]  

  • 26. Pharmaceutical company-sponsored drug trials: what are we to believe?
    Shekelle P
    J Clin Epidemiol; 2010 Feb; 63(2):126-7. PubMed ID: 19836207
    [No Abstract]   [Full Text] [Related]  

  • 27. Pharmaceutical company-sponsored drug trials: the system is broken.
    Gartlehner G; Fleg A
    J Clin Epidemiol; 2010 Feb; 63(2):128-9. PubMed ID: 19880288
    [No Abstract]   [Full Text] [Related]  

  • 28. Notable deals in the pharmaceutical industry in the fourth quarter of 2016.
    D'Souza P
    Drugs Today (Barc); 2017 Jan; 53(1):75-82. PubMed ID: 28387386
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law.
    Dinh TQ
    Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027
    [No Abstract]   [Full Text] [Related]  

  • 30. The FDA just says yes.
    MacPherson P
    Hosp Health Netw; 1996 May; 70(10):34-6, 38. PubMed ID: 8620201
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regulation of clinical research sponsored by pharmaceutical companies: a proposal.
    Sotelo J
    PLoS Med; 2006 Jul; 3(7):e306. PubMed ID: 16805651
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Obstacles and opportunities in new drug development.
    Kaitin KI
    Clin Pharmacol Ther; 2008 Feb; 83(2):210-2. PubMed ID: 18202685
    [No Abstract]   [Full Text] [Related]  

  • 33. Estimating the cost of new drug development: is it really 802 million dollars?
    Adams CP; Brantner VV
    Health Aff (Millwood); 2006; 25(2):420-8. PubMed ID: 16522582
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A role for two-stage pharmacoeconomic appraisal? Is there a role for interim approval of a drug for reimbursement based on modelling studies with subsequent full approval using phase III data?
    Hill S; Freemantle N
    Pharmacoeconomics; 2003; 21(11):761-7. PubMed ID: 12859218
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A critical tipping point.
    Zuckerman MB
    US News World Rep; 2002 Apr; 132(13):72. PubMed ID: 11993366
    [No Abstract]   [Full Text] [Related]  

  • 36. Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs.
    Amir E; Seruga B; Martinez-Lopez J; Kwong R; Pandiella A; Tannock IF; Ocaña A
    J Clin Oncol; 2011 Jun; 29(18):2543-9. PubMed ID: 21606435
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Noninferiority is (too) common in noninferiority trials.
    Soonawala D; Dekkers OM; Vandenbroucke JP; Egger M
    J Clin Epidemiol; 2016 Mar; 71():118-20. PubMed ID: 26607238
    [No Abstract]   [Full Text] [Related]  

  • 38. More Chinese get free drugs in clinical trials.
    Berton E
    Wall St J (East Ed); 2006 Feb; ():B1, B8. PubMed ID: 16528877
    [No Abstract]   [Full Text] [Related]  

  • 39. Easy ride for drug industry.
    McBane M
    Health Aff (Millwood); 2003; 22(4):259-60. PubMed ID: 12889775
    [No Abstract]   [Full Text] [Related]  

  • 40. Paying for pharmaceutical registration in developing countries.
    Kaplan WA; Laing R
    Health Policy Plan; 2003 Sep; 18(3):237-48. PubMed ID: 12917265
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.